Back to Trades
Sell4
LIGAND PHARMACEUTICALS INC
LGND
Total Value
$1.7M
Net $1.7M sold
Sales
$1.7M
3 transactions
Company Information
- Company Name
- LIGAND PHARMACEUTICALS INC
- Ticker Symbol
- LGND
- CIK
- 0000886163
Insider Information
- Name
- Aryeh Jason
- Role
- Director
- Location
- JUPITER, FL
Director
Filing Details
- Filing Date
- Sep 24, 2025
- Transaction Date
- Sep 23, 2025
- Accession Number
- 0002001011-25-000082
- Form Type
- 4
- Net Trading Amount
- -$1.7M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Sep 23, 2025 | Common Stock | 4,418 | $170.41 | Sale | $752.8K |
| Sep 23, 2025 | Common Stock | 4,628 | $170.96 | Sale | $791.2K |
| Sep 23, 2025 | Common Stock | 954 | $171.92 | Sale | $164.0K |
Footnotes
- (F1)The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $169.6625 to $170.6600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (F2)The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $170.6850 to $171.6050. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (F3)The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $171.7250 to $172.2400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (F4)All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.